Anew analysis from Xcenda applied the Institute for Clinical and Economic Review ’s (ICER) value assessments to state Medicaid programs inCalifornia,Massachusetts,Maryland,NevadaandNew York. The study found these one-size-fits-all value assessments could prevent or delay access to prescriptions to treat serious, complex conditions like Multiple Sclerosis (MS), rheumatoid arthritis (RA), non-small cell lung cancer (NSCLC) and psoriasis. (Source: The Catalyst)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read full article on RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.